cancerimmunotherapycelltherapydrugdeliveryimmunecheckpointblockadenanomedicineIn article number 1707112, Peng Huang, Zhen Gu, and co‐workers engineer cellular nanovesicles presenting PD‐1 receptors on their membranes, which enhance antitumor response by disrupting the PD‐1/PD‐L1 immune inhibitory axis. ...
Checkpoint blockade regulates T cell fate by supporting co-stimulation By tracking the fate of tumor-specific T cells mobilized in lymph nodes by dual blockade of PD-1 and TIGIT, we show that both exhausted T cells and effector T cells can emerge from a common progenitor. Signaling by the ...
2) What is the best combination therapy using PD-1 blockade? 3) What predictive biomarkers can be used to distinguish responsive and unresponsive patients? Here we review the development of immunotherapy targeting the PD-1/PD-L1 signaling pathway and discuss the issues that still need to be ...
Cancer immunotherapies, represented by immune checkpoint inhibitors (ICIs), have reshaped the treatment paradigm for both advanced non-small cell lung cancer and small cell lung cancer. Programmed death receptor-1/programmed death receptor ligand-1 (PD-1
The PD-L1/PD-1 signaling pathway is the gold standard for cancer immunotherapy. Therapeutic antibodies targeting PD-1, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), and PD-L1, including atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab (Bavencio) have received Food and ...
摘要: Cancer cells resist to the host immune antitumor response via multiple suppressive mechanisms, including the overexpression of PD-L1 that exhausts antigen-specific CD8(+) T cells t... 查看全部>>关键词: cancer immunotherapy cell therapy drug delivery immune checkpoint blockade nanomedicine ...
摘要: Inhibiting the protein PD-1 can activate T cells that trigger immune responses against tumour cells. But it emerges that, in mice, this immunotherapy exacerbates a cancer that involves the T cells themselves. See Letter p.121DOI: 10.1038/nature24759 被引量: 5 ...
Cancer cell-intrinsic PD-1 expression has been documented in multiple tumor types, including in melanoma. Here the authors identify a type I IFN-JAK/STAT signaling axis as a critical regulator of tumor cell-intrinsic PD-1 expression and targeting, with implications for cancer immunotherapy. Julia...
An immune attack against tumour cells in the host mediated by transplanted allogeneic T cells. Allogeneic Cells from a different individual that express different MHC alleles. About this article Cite this article Pardoll, D. The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer12...
O. et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front. Pharmacol. 8, 1–15 (2017). Google Scholar Munn, D. H. & Bronte, V. Immune suppressive mechanisms in the tumor microenvironment. Curr. Opin. Immunol....